Orforglipron framed as FDA‑approved pill
- The U.S. Food and Drug Administration approved Eli Lilly’s obesity pill Foundayo, the brand name for orforglipron, on April 1, 2026. - Lilly said Foundayo is the only glucagon-like peptide-1 weight-loss pill without food or water restrictions and began shipping prescriptions on April 6. - The approval gives Lilly an oral rival to injectable Wegovy and Zepbound in a fast-growing market. (fda.gov)
The Food and Drug Administration approved Eli Lilly’s obesity pill Foundayo, the brand name for orforglipron, on April 1, 2026. (fda.gov) (investor.lilly.com) Foundayo is cleared for adults with obesity, or adults with overweight plus at least one weight-related medical problem, alongside diet and exercise. (investor.lilly.com) (accessdata.fda.gov) The drug is a glucagon-like peptide-1, or GLP-1, medicine in pill form. These drugs mimic a gut hormone that helps people feel fuller and can lower appetite and blood sugar. (jamanetwork.com) (investor.lilly.com) Lilly said Foundayo can be taken once daily with or without food and without water restrictions, unlike earlier oral GLP-1 medicines with tighter dosing rules. (accessdata.fda.gov) (jamanetwork.com) That is the part that could change prescribing: the biggest obesity drugs on the market, including Novo Nordisk’s Wegovy and Lilly’s Zepbound, are injections. (jamanetwork.com) (investor.lilly.com) In Lilly’s late-stage ACHIEVE-1 trial in type 2 diabetes, patients on the highest dose lowered A1C by 1.6% and lost an average 16.0 pounds, or 7.9%, at 40 weeks. (investor.lilly.com) The approved label says the most common side effects were nausea, diarrhea, vomiting, constipation, indigestion and gastroesophageal reflux disease, with a boxed warning about thyroid C-cell tumors. (accessdata.fda.gov) FDA said the approval came 50 days after filing under the agency’s National Priority Voucher pilot, far ahead of the original January 20, 2027 target date. (fda.gov) Lilly said prescriptions were accepted immediately after approval, shipping began April 6, and broader U.S. retail pharmacy availability followed. (investor.lilly.com 1) (investor.lilly.com 2) The company said commercial coverage can start at $25 a month and self-pay pricing starts at $149 a month through Lilly’s launch programs. (investor.lilly.com) So the core fact in the Jerusalem Post framing is true on the approval, but incomplete on timing: Foundayo was approved on April 1, 2026, and the market is already moving from approval to rollout. (jpost.com) (fda.gov)
